Membrane defence against complement lysis: The structure and biological properties of CD59

The complement system is an important branch of the innate immune response, constituting a first line of defence against invading microorganisms which activate complement via both antibody-dependent and-independent mechanisms. Activation of complement leads to (a) a direct attack upon the activating cell surface by assembly of the pore-forming membrane attack complex (MAC), and (b) the generation of inflammatory mediators which target and recruit other branches of the immune system. However, uncontrolled complement activation can lead to widespread tissue damage in the host, since certain of the activation products, notably the fragment C3b and the C5b-7 complex, can bind nonspecifically to any nearby cell membranes. Therefore it is important that complement activation is tightly regulated. Our own cells express a number of membrane-bound control proteins which limit complement activation at the cell surface and prevent accidental complement-mediated damage. These include decay-accelerating factor, complement receptor 1 and membrane cofactor protein, all of which are active at the level of C3/C5 convertase formation. Until recently, cell surface control of MAC assembly had been attributed to a single 65-kD membrane protein called homologous restriction factor (alternatively named C8-binding protein and MAC-inhibiting protein). However a second MAC-inhibiting protein has since been discovered and it is now clear that this protein plays a major role in the control of membrane attack. This review charts the rapid progress made in elucidating the protein and gene structure, and the mechanism of action of this most recently discovered complement inhibitor, CD59.

[1]  Z. Fishelson COMPLEMENT EVASION BY PARASITES: SEARCH FOR “ACHILLES' HEEL” , 1991, Clinical and experimental immunology.

[2]  P. Sims,et al.  Regulatory control of complement on blood platelets. Modulation of platelet procoagulant responses by a membrane inhibitor of the C5b-9 complex. , 1989, The Journal of biological chemistry.

[3]  S. Maher,et al.  Amplified gene expression in CD59-transfected Chinese hamster ovary cells confers protection against the membrane attack complex of human complement. , 1991, Journal of Biological Chemistry.

[4]  T. Fujita,et al.  A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. , 1989, International immunology.

[5]  D. Cooper Is xenotransplantation a realistic clinical option? , 1992, Transplantation proceedings.

[6]  V. Hořejší,et al.  Large, detergent‐resistant complexes containing murine antigens Thy‐1 and Ly‐6 and protein tyrosine kinase p56lck , 1993, European journal of immunology.

[7]  M. Medof,et al.  Synthesis of aberrant decay-accelerating factor proteins by affected paroxysmal nocturnal hemoglobinuria leukocytes. , 1990, The Journal of clinical investigation.

[8]  S. Matsuo,et al.  Localization of 20‐kD homologous restriction factor (HRF20) in diseased human glomeruli. An immunofluorescence study , 1991, Clinical and experimental immunology.

[9]  D. Fleenor,et al.  Structure of the CD59-encoding gene: further evidence of a relationship to murine lymphocyte antigen Ly-6 protein. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[10]  B. Morgan,et al.  The sheep analogue of human CD59: purification and characterization of its complement inhibitory activity. , 1993, Immunology.

[11]  M. Shin,et al.  Cytolysis of nucleated cells by complement: cell death displays multi-hit characteristics. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[12]  C. Parker,et al.  PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND GLYCOSYL PHOSPHATIDYLINOSITOL ANCHORED PROTEINS THAT REGULATE COMPLEMENT , 1991, Clinical and experimental immunology.

[13]  H. Müller-Eberhard,et al.  Inhibition of antibody-dependent lymphocyte cytotoxicity by homologous restriction factor incorporated into target cell membranes , 1987, The Journal of experimental medicine.

[14]  R. Thompson,et al.  REACTIVE LYSIS: THE COMPLEMENT-MEDIATED LYSIS OF UNSENSITIZED CELLS , 1970, The Journal of experimental medicine.

[15]  J. Zajicek,et al.  Oligodendrocytes lack glycolipid anchored proteins which protect them against complement lysis. Restoration of resistance to lysis by incorporation of CD59. , 1992, Immunology.

[16]  D. Purcell,et al.  Complement regulatory proteins at the feto‐maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein(CD46) and decay accelerating factor (CD55) , 1992, European journal of immunology.

[17]  D. Fearon,et al.  Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. , 1982, Journal of immunology.

[18]  M. Rosenfeld,et al.  Synthesis of mannosylglucosaminylinositol phospholipids in normal but not paroxysmal nocturnal hemoglobinuria cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[19]  T. Fujita,et al.  Purification of 1F5 antigen that prevents complement attack on homologous cell membranes. , 1990, Journal of immunology.

[20]  D. Neuhaus,et al.  Sequence‐specific , 1993, Protein science : a publication of the Protein Society.

[21]  H. Müller-Eberhard,et al.  Deficiency of the homologous restriction factor in paroxysmal nocturnal hemoglobinuria , 1987, The Journal of experimental medicine.

[22]  A. Weetman,et al.  Antithyroid drugs and release of inflammatory mediators by complement-attacked thyroid cells , 1992, The Lancet.

[23]  N. Motoyama,et al.  Paroxysmal nocturnal hemoglobinuria due to hereditary nucleotide deletion in the HRF20 (CD59) gene , 1992, European journal of immunology.

[24]  B. Morgan,et al.  Isolation and characterization of the complement-inhibiting protein CD59 antigen from platelet membranes. , 1992, The Biochemical journal.

[25]  W. Knapp,et al.  GPI-anchored cell-surface molecules complexed to protein tyrosine kinases. , 1991, Science.

[26]  E. Appella,et al.  Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. , 1990, The EMBO journal.

[27]  H. Okada,et al.  Structural properties of the glycoplasmanylinositol anchor phospholipid of the complement membrane attack complex inhibitor CD59 , 1992, Clinical and experimental immunology.

[28]  Okada Hidechika,et al.  Species-specific inhibition by gycophorin of complement activation via the alternative pathway , 1983 .

[29]  J. Leddy,et al.  Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9. , 1979, The Journal of clinical investigation.

[30]  J. Sodetz,et al.  Analysis of the specific association of the eighth and ninth components of human complement: identification of a direct role for the alpha subunit of C8. , 1985, Biochemistry.

[31]  T. Fujita,et al.  Monoclonal antibodies capable of causing hemolysis of neuraminidase-treated human erythrocytes by homologous complement. , 1989, Journal of immunology.

[32]  T. Hideshima,et al.  20 KDa homologous restriction factor of complement resembles T cell activating protein. , 1989, Biochemical and biophysical research communications.

[33]  N. Cooper Complement evasion strategies of microorganisms. , 1991, Immunology today.

[34]  T. Kinoshita,et al.  Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. , 1990, The New England journal of medicine.

[35]  P. Sims,et al.  The human complement regulatory protein CD59 binds to the alpha-chain of C8 and to the "b"domain of C9. , 1992, The Journal of biological chemistry.

[36]  M. Nose,et al.  Tissue distribution of HRF20, a novel factor preventing the membrane attack of homologous complement, and its predominant expression on endothelial cells in vivo. , 1990, Immunology.

[37]  M. Tone,et al.  Transfection of human CD59 complementary DNA into rat cells confers resistance to human complement , 1991, European journal of immunology.

[38]  R. Schreiber,et al.  Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[39]  K. Hamilton,et al.  Regulatory control of the terminal complement proteins at the surface of human endothelial cells: neutralization of a C5b-9 inhibitor by antibody to CD59. , 1990, Blood.

[40]  W. Rosse Paroxysmal nocturnal hemoglobinuria: the biochemical defects and the clinical syndrome. , 1989, Blood reviews.

[41]  P. Sims,et al.  Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. , 1991, Journal of immunology.

[42]  N. E. Hansen,et al.  The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. , 1992, Blood.

[43]  J. Atkinson,et al.  Physiologic relevance of the membrane attack complex inhibitory protein CD59 in human seminal plasma: CD59 is present on extracellular organelles (prostasomes), binds cell membranes, and inhibits complement- mediated lysis , 1993, The Journal of experimental medicine.

[44]  C. Parker,et al.  Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. , 1989, The Journal of clinical investigation.

[45]  E. Reinherz,et al.  A soluble multimeric recombinant CD2 protein identifies CD48 as a low affinity ligand for human CD2: divergence of CD2 ligands during the evolution of humans and mice , 1993, The Journal of experimental medicine.

[46]  W. Rosse,et al.  Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria. , 1989, The Journal of clinical investigation.

[47]  T. Hughes,et al.  Isolation and characterization of a membrane protein from rat erythrocytes which inhibits lysis by the membrane attack complex of rat complement. , 1992, The Biochemical journal.

[48]  E. Simpson,et al.  A glycophospholipid anchor is required for Qa-2-mediated T cell activation , 1989, Nature.

[49]  M. Kazatchkine,et al.  Decreased Expression of the Membrane Inhibitor of Complement‐Mediated Cytolysis CD59 on T‐lymphocytes of HIV‐Infected Patients , 1992, AIDS.

[50]  A. Bothwell,et al.  Contribution of the N-linked carbohydrate of erythrocyte antigen CD59 to its complement-inhibitory activity. , 1992, The Journal of biological chemistry.

[51]  S. Meri,et al.  Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. , 1990, Immunology.

[52]  A. Weetman,et al.  Expression and function of membrane attack complex inhibitory proteins on thyroid follicular cells. , 1992, Immunology.

[53]  W. Hahn,et al.  Overlapping but nonidentical binding sites on CD2 for CD58 and a second ligand CD59. , 1992, Science.

[54]  J. Tschopp,et al.  Absence of homologous restriction factor does not affect CTL‐mediated cytolysis , 1989, European journal of immunology.

[55]  J. Takeda,et al.  Deficient surface expression of glycosylphosphatidylinositol-anchored proteins in B cell lines established from patients with paroxysmal nocturnal hemoglobinuria. , 1992, International immunology.

[56]  S. Meri,et al.  Human protectin (CD59), an 18-20-kD homologous complement restriction factor, does not restrict perforin-mediated lysis , 1990, The Journal of experimental medicine.

[57]  T. Takami,et al.  A case of paroxysmal nocturnal hemoglobinuria without deficiency of decay-accelerating factor on erythrocytes. , 1990, Blood.

[58]  N. Minato,et al.  Isolation and expression of the full-length cDNA encoding CD59 antigen of human lymphocytes. , 1990, DNA and cell biology.

[59]  E. Shevach,et al.  CD59 functions as a signal-transducing molecule for human T cell activation. , 1991, Journal of immunology.

[60]  P. Nicol,et al.  Studies on the terminal stages of complement lysis. , 1973, Immunology.

[61]  H. Okada,et al.  Species‐specific restriction of complement by HRF20 (CD59) generated by cDNA transfection , 1992, European journal of immunology.

[62]  I. Hanson,et al.  The human BDNF gene maps between FSHB and HVBS1 at the boundary of 11p13-p14. , 1992, Genomics.

[63]  N. Minato,et al.  Cytoprotective effect of CD59 antigen on xenotransplantation immunity. , 1992, Transplantation Proceedings.

[64]  E. Shevach,et al.  Ly-6: a multigene family in search of a function. , 1989, Immunology today.

[65]  P. Robinson,et al.  Phosphatidylinositol membrane anchors and T-cell activation. , 1991, Immunology today.

[66]  K. Austen,et al.  Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[67]  M. Borowitz,et al.  Defective glycosylphosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglobinuria granulocytes. , 1992, Blood.

[68]  R. Schmidt,et al.  Affected paroxysmal nocturnal hemoglobinuria T lymphocytes harbor a common defect in assembly of N-acetyl-D-glucosamine inositol phospholipid corresponding to that in class A Thy-1- murine lymphoma mutants. , 1992, The Journal of biological chemistry.

[69]  K. Inoue,et al.  The role of the C9b domain in the binding of C9 molecules to EAC1-8 defined by monoclonal antibodies to C9. , 1988, Journal of Immunology.

[70]  A. Dalmasso,et al.  REACTION OF COMPLEMENT WITH ENDOTHEUAL CELLS IN A MODEL OF XEN0TRANSPLANTATION , 1991, Clinical and experimental immunology.

[71]  R. Taguchi,et al.  Complete deficiency of 20 KDa homologous restriction factor (HRF20) and restoration with purified HRF20. , 1989, Biochemical and biophysical research communications.

[72]  Y. Sugita,et al.  Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels. , 1988, Journal of biochemistry.

[73]  I. Hilgert,et al.  Characterization of a broadly expressed human leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositol. , 1989, Molecular immunology.

[74]  D. Roelcke,et al.  Glycophorin A inhibits lysis by the complement attack phase. , 1983, Immunobiology.

[75]  T. Yasuda,et al.  Differing reactivities of human and guinea-pig complement on haptenized liposomes via the alternative pathway. , 1983, Molecular immunology.

[76]  I. Rooney,et al.  Membrane attack complex (MAC)-mediated damage to spermatozoa: protection of the cells by the presence on their membranes of MAC inhibitory proteins. , 1992, Immunology.

[77]  H. Waldmann,et al.  Gene structure of human CD59 and demonstration that discrete mRNAs are generated by alternative polyadenylation. , 1992, Journal of molecular biology.

[78]  D. Lublin Glycosyl-phosphatidylinositol anchoring of membrane proteins. , 1992, Current topics in microbiology and immunology.

[79]  K. Yasukawa,et al.  Molecular cloning and characterization of MACIF, an inhibitor of membrane channel formation of complement. , 1989, Journal of biochemistry.

[80]  M. Lederman,et al.  Heightened complement sensitivity of acquired immunodeficiency syndrome lymphocytes related to diminished expression of decay-accelerating factor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[81]  W. Philbrick,et al.  The CD59 antigen is a structural homologue of murine Ly‐6 antigens but lacks interferon inducibility , 1990, European journal of immunology.

[82]  T. Huizinga,et al.  The Pi-linked receptor FcRIII is released on stimulation of neutrophils , 1988, Nature.

[83]  D. Hourcade,et al.  Expression of human decay accelerating factor or membrane cofactor protein genes on mouse cells inhibits lysis by human complement. , 1992, Transplantation proceedings.

[84]  V. Hořejší,et al.  Association of the CD59 and CD55 cell surface glycoproteins with other membrane molecules. , 1991, Journal of immunology.

[85]  V. Hořejší,et al.  The nature of large noncovalent complexes containing glycosyl-phosphatidylinositol-anchored membrane glycoproteins and protein tyrosine kinases. , 1992, Journal of immunology.

[86]  A. Bernard,et al.  A 19-kDa human erythrocyte molecule H19 is involved in rosettes, present on nucleated cells, and required for T cell activation. Comparison of the roles of H19 and LFA-3 molecules in T cell activation. , 1989, Journal of immunology.

[87]  B. Fleckenstein,et al.  Herpesvirus saimiri has a gene specifying a homologue of the cellular membrane glycoprotein CD59. , 1992, Virology.

[88]  C. Browning,et al.  On Chemical Combination and Toxic Action as Exemplified in Haemolytic Sera , 1904, Proceedings of the Royal Society of London.

[89]  G. Klein,et al.  Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum‐mediated lysis , 1992, European journal of immunology.

[90]  M. Deckert,et al.  CD59 molecule: A second ligand for CD2 in T cell adhesion , 1992, European journal of immunology.

[91]  M. Daha,et al.  CD59 expressed by human endothelial cells functions as a protective molecule against complement‐mediated lysis , 1992, European journal of immunology.

[92]  J. Richardson,et al.  The toxin-agglutinin fold. A new group of small protein structures organized around a four-disulfide core. , 1980, The Journal of biological chemistry.

[93]  H. Müller-Eberhard,et al.  Self-protection of cytotoxic lymphocytes: a soluble form of homologous restriction factor in cytoplasmic granules. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[94]  V. Nussenzweig,et al.  Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein , 1986, The Journal of experimental medicine.

[95]  Michael Loran Dustin,et al.  Deficiency of lymphocyte function-associated antigen 3 (LFA-3) in paroxysmal nocturnal hemoglobinuria. Functional correlates and evidence for a phosphatidylinositol membrane anchor , 1987, The Journal of experimental medicine.

[96]  T. Hideshima,et al.  HRF20, a membrane inhibitor of complement attack, does not protect cells from the cytotoxic reaction by lymphokine activated killer cells. , 1990, Biochemical and biophysical research communications.

[97]  W. Roberts,et al.  Structural basis for variations in the sensitivity of human decay accelerating factor to phosphatidylinositol-specific phospholipase C cleavage. , 1990, Journal of immunology.

[98]  D L Simmons,et al.  CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells , 1989, The Journal of experimental medicine.

[99]  D. Fearon ANTI‐INFLAMMATORY AND IMMUNOSUPPRESSIVE EFFECTS OF RECOMBINANT SOLUBLE COMPLEMENT RECEPTORS , 1991, Clinical and experimental immunology.

[100]  J. Atkinson,et al.  Evolution of the complement system. , 1991, Immunology today.

[101]  D. Anstee,et al.  New monoclonal antibodies in CD59: use for the analysis of peripheral blood cells from paroxysmal nocturnal haemoglobinuria (PNH) patients and for the quantitation of CD59 on normal and decay accelerating factor (DAF)-deficient erythrocytes. , 1992, Immunology.

[102]  P. Sims,et al.  The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. , 1990, Journal of immunology.

[103]  R. Flavell,et al.  The glycosyl phosphatidylinositol anchor is critical for Ly-6A/E- mediated T cell activation , 1991, The Journal of cell biology.

[104]  S. Meri,et al.  The complement‐inhibiting protein, Protectin (CD59 antigen), is present and functionally active on glomerular epithelial cells , 1991, Clinical and experimental immunology.

[105]  J. Toutant,et al.  Conversion of human erythrocyte acetylcholinesterase from an amphiphilic to a hydrophilic form by phosphatidylinositol-specific phospholipase C and serum phospholipase D. , 1989, European journal of biochemistry.

[106]  I. Rooney,et al.  Characterization of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluid. , 1992, Immunology.

[107]  J. Pepose,et al.  Differential expression of the complement regulatory proteins in the human eye. , 1993, Investigative ophthalmology & visual science.

[108]  V. Nussenzweig,et al.  H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complement. , 1990, Cellular immunology.

[109]  T. Springer,et al.  Distinct restriction of complement- and cell-mediated lysis. , 1989, Journal of immunology.

[110]  M. Telen,et al.  The Inab phenotype: characterization of the membrane protein and complement regulatory defect. , 1989, Blood.

[111]  V. Nussenzweig,et al.  Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[112]  H. Müller-Eberhard,et al.  Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[113]  B. Morgan,et al.  Expression of the glycosylphosphatidylinositol-linked complement-inhibiting protein CD59 antigen in insect cells using a baculovirus vector. , 1993, The Biochemical journal.

[114]  F. Ruddle,et al.  Murine Ly-6 multigene family is located on chromosome 15. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[115]  S. Barnum,et al.  Expression of decay-accelerating factor (CD55), membrane cofactor protein (CD46) and CD59 in the human astroglioma cell line, D54-MG, and primary rat astrocytes , 1993, Journal of Neuroimmunology.

[116]  M. Shin,et al.  Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor. , 1986, Journal of immunology.

[117]  S. Meri,et al.  Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[118]  E. Podack,et al.  A central role of perforin in cytolysis? , 1991, Annual review of immunology.

[119]  P. Thomas,et al.  The glycophosphatidylinositol-anchored Thy-1 molecule interacts with the p60fyn protein tyrosine kinase in T cells. , 1992, The Journal of biological chemistry.

[120]  W. Bickmore,et al.  Colocalization of the human CD59 gene to 11p13 with the MIC11 cell surface antigen. , 1993, Genomics.

[121]  M. Telen,et al.  The acetylcholinesterase defect in paroxysmal nocturnal hemoglobinuria: evidence that the enzyme is absent from the cell membrane , 1985 .

[122]  T. Fujita,et al.  Signal transduction through decay-accelerating factor. Interaction of glycosyl-phosphatidylinositol anchor and protein tyrosine kinases p56lck and p59fyn 1. , 1992, Journal of immunology.